A detailed history of Arizona State Retirement System transactions in Prothena Corp Public LTD CO stock. As of the latest transaction made, Arizona State Retirement System holds 10,064 shares of PRTA stock, worth $140,996. This represents 0.0% of its overall portfolio holdings.

Number of Shares
10,064
Previous 9,776 2.95%
Holding current value
$140,996
Previous $201,000 16.42%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$16.73 - $24.79 $4,818 - $7,139
288 Added 2.95%
10,064 $168,000
Q2 2024

Aug 05, 2024

SELL
$19.54 - $26.15 $25,108 - $33,602
-1,285 Reduced 11.62%
9,776 $201,000
Q1 2024

May 07, 2024

SELL
$24.75 - $40.66 $4,059 - $6,668
-164 Reduced 1.46%
11,061 $273,000
Q4 2023

Jan 24, 2024

SELL
$32.31 - $52.32 $1,292 - $2,092
-40 Reduced 0.36%
11,225 $407,000
Q3 2023

Nov 06, 2023

BUY
$47.3 - $70.6 $8,703 - $12,990
184 Added 1.66%
11,265 $543,000
Q2 2023

Aug 01, 2023

BUY
$48.26 - $78.59 $61,241 - $99,730
1,269 Added 12.93%
11,081 $756,000
Q1 2023

Apr 27, 2023

BUY
$46.97 - $58.27 $25,551 - $31,698
544 Added 5.87%
9,812 $475,000
Q4 2022

Feb 07, 2023

BUY
$52.05 - $65.0 $18,946 - $23,660
364 Added 4.09%
9,268 $558,000
Q3 2022

Nov 07, 2022

BUY
$25.16 - $60.63 $1,207 - $2,910
48 Added 0.54%
8,904 $540,000
Q2 2022

Jul 28, 2022

BUY
$22.73 - $39.98 $886 - $1,559
39 Added 0.44%
8,856 $240,000
Q1 2022

May 04, 2022

BUY
$30.27 - $49.22 $9,989 - $16,242
330 Added 3.89%
8,817 $322,000
Q4 2021

Feb 04, 2022

BUY
$42.11 - $73.26 $2,695 - $4,688
64 Added 0.76%
8,487 $419,000
Q3 2021

Nov 12, 2021

BUY
$48.2 - $78.89 $40,054 - $65,557
831 Added 10.95%
8,423 $600,000
Q2 2021

Aug 02, 2021

BUY
$21.63 - $57.65 $164,214 - $437,678
7,592 New
7,592 $390,000

Others Institutions Holding PRTA

About PROTHENA CORP PUBLIC LTD CO


  • Ticker PRTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,922,800
  • Market Cap $657M
  • Description
  • Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...
More about PRTA
Track This Portfolio

Track Arizona State Retirement System Portfolio

Follow Arizona State Retirement System and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Arizona State Retirement System, based on Form 13F filings with the SEC.

News

Stay updated on Arizona State Retirement System with notifications on news.